Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Debt: 2013-2024

Historic Non-Current Debt for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $601.6 million.

  • Amphastar Pharmaceuticals' Non-Current Debt rose 2.03% to $608.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $608.6 million, marking a year-over-year increase of 2.03%. This contributed to the annual value of $601.6 million for FY2024, which is 2.04% up from last year.
  • Amphastar Pharmaceuticals' Non-Current Debt amounted to $601.6 million in FY2024, which was up 2.04% from $589.6 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Non-Current Debt registered a high of $601.6 million during FY2024, and its lowest value of $34.2 million during FY2020.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Non-Current Debt value was $589.6 million (recorded in 2023), while the average stood at $421.3 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Non-Current Debt dropped by 13.22% in 2020 and then surged by 709.43% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Non-Current Debt (Yearly) stood at $34.2 million in 2020, then soared by 118.73% to $74.8 million in 2021, then declined by 2.59% to $72.8 million in 2022, then spiked by 709.43% to $589.6 million in 2023, then climbed by 2.04% to $601.6 million in 2024.